{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:06:20Z","timestamp":1753891580404,"version":"3.41.2"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Light chain (AL) amyloidosis stands as the most prevalent subtype of systemic amyloidosis, encompassing a group of rare diseases. Here, we evaluated the scientific landscape of AL amyloidosis to investigate research trends and identify hotspots within the field.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Relevant studies on AL amyloidosis published over the past two decades were retrieved from the Web of Science Core Collection. The publications between 2005 and 2024 were subjected to bibliometric analyses, leveraging tools including CiteSpace, VOSviewer, RStudio and MS Excel to analyse and visualize the annual publication trend, co-occurrence patterns, collaborative networks among countries, organizations, and authors. Burst keywords and references were also examined to obtain the research history, and emerging hotspots.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The bibliometric analysis included 2,864 articles published between 2005 and 2024. The most productive journal is <jats:italic>Amyloid-Journal of Protein Folding Disorders<\/jats:italic>. The United States, along with several developed nations, emerges as a dominant force in international AL amyloidosis research. \u201cAL amyloidosis\u201d and \u201ccardiac amyloidosis\u201d were the primary hotspots over the past two decades, and \u201cBiomarkers,\u201d \u201cCardiac amyloidosis,\u201d and \u201ctreatment\u201d would be future trends.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This bibliometric analysis examined the research developments in AL amyloidosis over the past two decades using bibliometric software. Recent research in this field primarily focuses on two main areas: clinical diagnosis and treatment of AL amyloidosis, as well as cardiac amyloidosis. Emphasis is placed on understanding the mechanisms underlying immunoglobulin light chain aggregation and deposition to mitigate organ involvement.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1441032","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T11:05:49Z","timestamp":1722337549000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A bibliometric analysis of light chain amyloidosis from 2005 to 2024: research trends and hot spots"],"prefix":"10.3389","volume":"11","author":[{"given":"Xiangdong","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Cong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14797\/mdcvj.1070","article-title":"Light chain amyloidosis: epidemiology, staging, and prognostication","volume":"18","author":"Baker","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.3324\/haematol.2022.282484","article-title":"Amyloidogenic light chains impair plasma cell survival","volume":"108","author":"Pick","year":"2023","journal-title":"Haematologica"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood.2021014613","article-title":"Daratumumab in AL amyloidosis","volume":"140","author":"Wechalekar","year":"2022","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/13506129.2021.1877129","article-title":"Early events in light chain aggregation at physiological pH reveal new insights on assembly, stability, and aggregate dissociation","volume":"28","author":"Misra","year":"2021","journal-title":"Amyloid"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jbusres.2021.04.070","article-title":"How to conduct a bibliometric analysis: an overview and guidelines","volume":"133","author":"Donthu","year":"2021","journal-title":"J Bus Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40037-021-00695-4","article-title":"Bibliometrics: methods for studying academic publishing","volume":"11","author":"Ninkov","year":"2022","journal-title":"Perspect Med Educ"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1073\/pnas.0307513100","article-title":"Searching for intellectual turning points: progressive knowledge domain visualization","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5195\/jmla.2022.1434","article-title":"VOSviewer and bibliometrix","volume":"110","author":"Arruda","year":"2022","journal-title":"J Med Libr Assoc"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, tours, France, 18\u201322 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and n-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with al amyloidosis: an 8-year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"102826","DOI":"10.1016\/j.fsigen.2023.102826","article-title":"Forty years of research and development on forensic genetics: a bibliometric analysis","volume":"63","author":"Stasi","year":"2023","journal-title":"Forensic Sci Int Genet"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"10916","DOI":"10.3390\/ijms222010916","article-title":"Biomarkers in al amyloidosis","volume":"22","author":"Fotiou","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e004409","DOI":"10.1161\/CIRCHEARTFAILURE.117.004409","article-title":"Prognostic value of N-terminal pro-B-type natriuretic peptide levels in heart failure patients with and without atrial fibrillation","volume":"10","author":"Kristensen","year":"2017","journal-title":"Circ Heart Fail"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in al amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/S0140-6736(03)13396-X","article-title":"Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins","volume":"361","author":"Dispenzieri","year":"2003","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","article-title":"The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis","volume":"116","author":"Palladini","year":"2010","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1182\/blood-2010-02-267708","article-title":"Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin t assay","volume":"116","author":"Kristen","year":"2010","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.jacc.2012.04.043","article-title":"Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers","volume":"60","author":"Buss","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum n-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in al amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4065\/83.3.297","article-title":"Serum uric acid: novel prognostic factor in primary systemic amyloidosis","volume":"83","author":"Kumar","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/13506129.2017.1293644","article-title":"Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal al amyloidosis","volume":"24","author":"Palladini","year":"2017","journal-title":"Amyloid"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome","volume":"130","author":"Milani","year":"2017","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41375-019-0655-x","article-title":"Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in al amyloidosis","volume":"34","author":"Muchtar","year":"2020","journal-title":"Leukemia"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3109\/13506129.2013.854766","article-title":"Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan\/dexamethasone","volume":"21","author":"Bochtler","year":"2014","journal-title":"Amyloid"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/bjh.14908","article-title":"Immunoparesis defined by heavy + light chain suppression is a novel marker of long-term outcomes in cardiac al amyloidosis","volume":"179","author":"Sachchithanantham","year":"2017","journal-title":"Br J Haematol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ajh.25746","article-title":"Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis","volume":"95","author":"Sidana","year":"2020","journal-title":"Am J Hematol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/ajh.25576","article-title":"Prevalence and prognostic value of D-dimer elevation in patients with al amyloidosis","volume":"94","author":"Pudusseri","year":"2019","journal-title":"Am J Hematol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/ajh.24001","article-title":"Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Am J Hematol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/CRD.0b013e3181cfb646","article-title":"Osteopontin in cardiovascular disease: a potential therapeutic target","volume":"18","author":"Waller","year":"2010","journal-title":"Cardiol Rev"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000443519","article-title":"Endothelial function and cardiovascular autonomic activity in neurally mediated syncope","volume":"134","author":"Park","year":"2016","journal-title":"Cardiology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12968-019-0564-1","article-title":"Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis","volume":"21","author":"Arenja","year":"2019","journal-title":"J Cardiovasc Magn Reson"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12968-017-0419-6","article-title":"The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis","volume":"20","author":"Lin","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1182\/blood-2017-12-819904","article-title":"Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis","volume":"131","author":"Kastritis","year":"2018","journal-title":"Blood"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/nm.4362","article-title":"A tripartite complex of suPAR, APOL1 risk variants and \u03b1v\u03b23 integrin on podocytes mediates chronic kidney disease","volume":"23","author":"Hayek","year":"2017","journal-title":"Nat Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjh.16112","article-title":"A risk stratification for systemic immunoglobulin light-chain amyloidosis with renal involvement","volume":"187","author":"Li","year":"2019","journal-title":"Br J Haematol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American heart association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European society of cardiology working group on myocardial and pericardial diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.carpath.2015.07.008","article-title":"Cardiac amyloidosis: pathology, nomenclature, and typing","volume":"24","author":"Maleszewski","year":"2015","journal-title":"Cardiovasc Pathol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","article-title":"Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients","volume":"88","author":"Comenzo","year":"1996","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N Engl J Med"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/blood-2016-08-730978","article-title":"The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity","volume":"129","author":"Oliva","year":"2017","journal-title":"Blood"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic al amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"101207","DOI":"10.1016\/j.blre.2024.101207","article-title":"Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis","volume":"66","author":"Wang","year":"2024","journal-title":"Blood Rev"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1441032\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T11:05:53Z","timestamp":1722337553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1441032\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":55,"alternative-id":["10.3389\/fmed.2024.1441032"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1441032","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"article-number":"1441032"}}